Actinium Pharmaceuticals’ (ATNM) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) in a research report released on Monday, Benzinga reports. They currently have a $50.00 price target on the biotechnology company’s stock.

Other equities analysts have also issued reports about the stock. Maxim Group boosted their price target on shares of Actinium Pharmaceuticals from $20.00 to $30.00 and gave the stock a buy rating in a research report on Tuesday, March 19th. StockNews.com lowered Actinium Pharmaceuticals from a hold rating to a sell rating in a research report on Tuesday, March 19th. Finally, Cantor Fitzgerald reaffirmed an overweight rating and issued a $21.00 price target on shares of Actinium Pharmaceuticals in a report on Monday, April 1st. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of Moderate Buy and an average target price of $25.72.

Actinium Pharmaceuticals Stock Up 8.2 %

Shares of Actinium Pharmaceuticals stock opened at $7.43 on Monday. The company has a market cap of $218.44 million, a price-to-earnings ratio of -4.06 and a beta of 0.01. Actinium Pharmaceuticals has a 12 month low of $4.00 and a 12 month high of $9.86.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) last posted its quarterly earnings data on Friday, March 29th. The biotechnology company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.21. The firm had revenue of $0.08 million during the quarter. As a group, equities research analysts anticipate that Actinium Pharmaceuticals will post -1.87 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in ATNM. Sanders Morris Harris LLC purchased a new stake in Actinium Pharmaceuticals in the 1st quarter valued at about $78,000. Creative Financial Designs Inc. ADV boosted its stake in Actinium Pharmaceuticals by 19.1% during the fourth quarter. Creative Financial Designs Inc. ADV now owns 19,800 shares of the biotechnology company’s stock worth $101,000 after buying an additional 3,175 shares during the period. Finally, Brandywine Global Investment Management LLC acquired a new stake in shares of Actinium Pharmaceuticals during the third quarter valued at about $1,033,000. 27.50% of the stock is currently owned by institutional investors and hedge funds.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.